Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248420 | 0.94 | TDP1 (0.74) | TDP1KMT2AABCG2MMP13HPGD | |
| SCHEMBL12799554 | 0.92 | TDP1 (0.72) | TDP1KMT2AABCG2MMP13HPGD | |
| SCHEMBL4251856 | 0.90 | TDP1 (0.68) | TDP1KMT2AABCG2HPGDTP53 | |
| SCHEMBL4242119 | 0.89 | TDP1 (0.67) | TDP1KMT2AABCG2MMP13HPGD | |
| SCHEMBL4245813 | 0.88 | TDP1 (0.64) | TDP1KMT2AABCG2TP53MEN1 | |
| SCHEMBL4248962 | 0.88 | TDP1 (0.65) | TDP1KMT2AABCG2MMP13HPGD | |
| SCHEMBL4240864 | 0.85 | TDP1 (0.61) | TDP1KMT2AABCG2HPGDTP53 | |
| SCHEMBL4244977 | 0.83 | TDP1 (0.61) | TDP1KMT2AMMP13HPGDALDH1A1 | |
| SCHEMBL3148208 | 0.82 | TDP1 (1.00) | TDP1KMT2AABCG2MMP13TP53 | |
| SCHEMBL4249944 | 0.82 | TDP1 (0.56) | TDP1KMT2AALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2151431-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | CBR1, CBR3, GBA1 | TDP1 4368/4885KMT2A 1752/4885ABCG2 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.